Biogen has bolstered its pipeline by licensing ex-US rights to a drug for Dravet syndrome – a rare form of epilepsy – from ...

Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is ...

Goldman Sachs lowered the firm’s price target on Biogen (BIIB) to $245 from $281 but keeps a Buy rating on the shares. The firm cites the ...

Canaccord lowered the firm’s price target on Biogen (BIIB) to $265 from $298 and keeps a Buy rating on the shares. The firm noted the market ...

Biogen expects 2025 non-GAAP EPS of $15.25-$16.25 and a mid ... Guidance language shifted slightly, with a lower EPS range for 2025 ($15.25-$16.25 vs. $16.10-$16.60 for 2024) reflecting anticipated MS ...

Q4 2024 Earnings Call Transcript February 12, 2025 Operator: Good morning. My name is Jennifer and I will be your conference ...

Several large Massachusetts employers have filed annual reports with federal securities regulators that are notable for ...

After receiving and considering an "unsolicited" buyout offer from partner Biogen, Sage Therapeutics is kicking the tires on a range of strategic options. However, the company's board of directors ...

Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Biogen's whale activity within a strike price range from $130.0 to $250.0 in the ...